PneumoniaPRE-EPPANCT07703852
Pilot Study to Study the Time Between Pleuropulmonary Ultrasound and Antibiotic Therapy Prescription in Patients Admitted to the Emergency Department for Suspected Pneumonia
An observational study of Pneumonia, run by University Hospital, Grenoble.
Trial summary
Pneumonia is a common pathology with significant morbidity and mortality. It is recommended in his diagnostic approach to perform either a chest X-ray or a pleuropulmonary ultrasound. Previous studies have shown the advantages of ultrasound in terms of diagnostic performance cost and patient irradiation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pneumonia
- What is being tested?
- Pleuropulmonary ultrasound performed by the investigator for patient with suspicion od Pneumonia
- Type of treatment
- Surgery or procedure
- How many people
- 15 participants
- Where
- No sites listed yet
- Study dates
- 13 Jul 2026to 30 Sep 2026
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patient admitted in the emergency department of Grenoble Alpes University Hospital for suspicion of Pneumonia
Who may be able to join
- Patient over 18 years admitted the the emergency department of Grenoble Alpes University Hospital with respiratory symptoms (cough and/or dyspnea, fever).
- No objection by the subject to the study
- Affiliated to the french social security system (or equivalent)
Who cannot join
- Patient admitted to a life-threatening emergency
- Patient already on antibiotic therapy on admission
- Patient excluded from another study
- Patient with respiratory signs following chest trauma
- Unable to communicate or non-french speaking patients or those with impaired comprehension or consciousness
- Protected persons referred to in articles L1121-6 and L1121-8 of French public health code (deprived of liberty, tutorship or curatorship)
- The patient already enrolled in the study
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Pneumonia is a common pathology with significant morbidity and mortality. It is recommended in his diagnostic approach to perform either a chest X-ray or a pleuropulmonary ultrasound. Previous studies have shown the advantages of ultrasound in terms of diagnostic performance cost and patient irradiation. However, it remains little used in clinical practice.
Read the detailed description
The study will be conducted in the Emergency Department of grenoble University Hospital.
Patient admitted to the emergency department for respiratory symptoms (cough, fever, and/or dyspnea) will be enrolled in the study according to the inclusion and non-inclusion criteria and after obtaining his consent.
The investigator will perform the pleuropulmonary ultrasound following the clinical examination carried out by the physician in charge of the patient.
The patient's care is unaffected by the pleuropulmonary ultrasound's outcome, which is unknown to the physician in charge of the patient.
Data collection after the patient's discharge from the emergency department.
- Conditions
- Pneumonia
- Being tested
- Pleuropulmonary ultrasound performed by the investigator for patient with suspicion od Pneumonia
- Keywords
- Pneumonia, Pleuropulmonary ultrasound, Antibiotic
- Medical subject headings
- Pneumonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pleuropulmonary ultrasound performed by the investigator for patient with suspicion od PneumoniaProcedure or surgery
In addition to the traditional management done by the physician at the patient's expense (such as clinical examination and paraclinical examinations like biology, chest X-ray, etc.), the investigator will perform pleuropulmonary ultrasound.
| Study group | Role | What they receive |
|---|---|---|
| Patient admitted for suspicion of Pneumonia | Patient admitted in emergency department of Grenoble Alpes University Hospital for suspicion of Pneumonia Receives: Procedure: Pleuropulmonary ultrasound performed by the investigator for patient with suspicion od Pneumonia |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time between the antibiotic prescription and the pleuropulmonary ultrasonography used to detect pneumonia
Time between the antibiotic prescription and the pleuropulmonary ultrasonography used to detect pneumonia
Measured: 1 hour
Secondary outcomes (4)
Calculation of the predictive values of the pleuropulmonary ultrasound for pneumonia diagnosis
Calculation of the predictive values of the pleuropulmonary ultrasound for pneumonia diagnosis: area under the curve, sensitivity, specificity, positive predictive value, negative predictive value.
Measured: 1 day
duration of performing the pleuropulmonary ultrasound
duration of performing the pleuropulmonary ultrasound
Measured: 5 minutes
Time between the patient's admission to the emergency department and the completion of the pleuropulmonary ultrasound
Time between the patient's admission to the emergency department and the completion of the pleuropulmonary ultrasound
Measured: 1 hour
4. Time between the performance of the pleuropulmonary ultrasound and the performance of the chest X-ray
- Time between the performance of the pleuropulmonary ultrasound and the performance of the chest X-ray
Measured: 2 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start13 Jul 2026 (estimated)
- Primary completion30 Aug 2026 (estimated)
- Study completion30 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PneumoniaStudies of the same condition, open and under way.
- More trials run by University Hospital, GrenobleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 15 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- University Hospital, Grenoble
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Alice GREMBER, MD, Principal investigator, University Hospital, Grenoble
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07703852
- Sponsor's protocol ID
- 38RC26.0148
- Other IDs
- IDRCB :2026-A00930-51
- Acronym
- PRE-EPPA
- Status last verified
- Jul 2026
- First submitted
- 9 Jul 2026
- Last updated
- 14 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The international writing and publication rules (The Uniform Requirements for Manuscripts of the ICMJE, April 2010) will be followed. The minimum anonymized source data for performing the statistical analysis will be made public at the time of publication, with the article, or deposited in an appropriate public database. Other anonymized data may be available from the principal investigator upon reasonable request and with the consent of the sponsor. In accordance with the French law n ° 2002-303 of March 4th, 2002, the subjects can be informed, at their request, of the overall results of the research. In this study, the investigators commit to individually communicating the overall results to each subject participating in the research by a short (popularized) summary and associated with a copy of the scientific article.
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Study to Study the Time Between Pleuropulmonary Ultrasound and Antibiotic Therapy Prescription in Patients Admitted to the Emergency Department for Suspected Pneumonia
- ClinicalTrials.gov ID
- NCT07703852
- Acronym / sponsor ID
- PRE-EPPA / 38RC26.0148
- Conditions
- Pneumonia
- Keywords
- Pneumonia, Pleuropulmonary ultrasound, Antibiotic
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- University Hospital, GrenobleUniversity, hospital or other
- Study start
- 13 Jul 2026 (estimated)
- Primary completion
- 30 Aug 2026 (estimated)
- Study completion
- 30 Sep 2026 (estimated)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pneumonia is a common pathology with significant morbidity and mortality. It is recommended in his diagnostic approach to perform either a chest X-ray or a pleuropulmonary ultrasound. Previous studies have shown the advantages of ultrasound in terms of diagnostic performance cost and patient irradiation. However, it remains little used in clinical practice.
Detailed description
The study will be conducted in the Emergency Department of grenoble University Hospital.
Patient admitted to the emergency department for respiratory symptoms (cough, fever, and/or dyspnea) will be enrolled in the study according to the inclusion and non-inclusion criteria and after obtaining his consent.
The investigator will perform the pleuropulmonary ultrasound following the clinical examination carried out by the physician in charge of the patient.
The patient's care is unaffected by the pleuropulmonary ultrasound's outcome, which is unknown to the physician in charge of the patient.
Data collection after the patient's discharge from the emergency department.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patient admitted for suspicion of Pneumonia | – | Procedure: Pleuropulmonary ultrasound performed by the investigator for patient with suspicion od PneumoniaPatient admitted in emergency department of Grenoble Alpes University Hospital for suspicion of Pneumonia |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patient admitted in the emergency department of Grenoble Alpes University Hospital for suspicion of Pneumonia
Key inclusion criteria (3 listed)
- Patient over 18 years admitted the the emergency department of Grenoble Alpes University Hospital with respiratory symptoms (cough and/or dyspnea, fever).
- No objection by the subject to the study
- Affiliated to the french social security system (or equivalent)
Key exclusion criteria (7 listed)
- Patient admitted to a life-threatening emergency
- Patient already on antibiotic therapy on admission
- Patient excluded from another study
- Patient with respiratory signs following chest trauma
- Unable to communicate or non-french speaking patients or those with impaired comprehension or consciousness
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pleuropulmonary ultrasound performed by the investigator for patient with suspicion od PneumoniaIn addition to the traditional management done by the physician at the patient's expense (such as clinical examination and paraclinical examinations like biology, chest X-ray, etc.), the investigator will perform pleuropulmonary ultrasound. | Procedure or surgery | Patient admitted for suspicion of Pneumonia |
Primary outcome
Time between the antibiotic prescription and the pleuropulmonary ultrasonography used to detect pneumonia
Time frame: 1 hour
Time between the antibiotic prescription and the pleuropulmonary ultrasonography used to detect pneumonia
4 secondary outcomes
Calculation of the predictive values of the pleuropulmonary ultrasound for pneumonia diagnosis
Time frame: 1 day
duration of performing the pleuropulmonary ultrasound
Time frame: 5 minutes
Time between the patient's admission to the emergency department and the completion of the pleuropulmonary ultrasound
Time frame: 1 hour
4. Time between the performance of the pleuropulmonary ultrasound and the performance of the chest X-ray
Time frame: 2 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
- Individual participant dataSharing planned: Yes. The international writing and publication rules (The Uniform Requirements for Manuscripts of the ICMJE, April 2010) will be followed. The minimum anonymized source data for performing the statistical analysis will be made public at the time of publication, with the article, or deposited in an appropriate public database. Other anonymized data may be available from the principal investigator upon reasonable request and with the consent of the sponsor. In accordance with the French law n ° 2002-303 of March 4th, 2002, the subjects can be informed, at their request, of the overall results of the research. In this study, the investigators commit to individually communicating the overall results to each subject participating in the research by a short (popularized) summary and associated with a copy of the scientific article.
Related trials for Pneumonia
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Alice GREMBER, MD principal investigator
University Hospital, Grenoble
Questions about this trial
What is this clinical trial studying?
An observational study of Pneumonia, run by University Hospital, Grenoble.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alice GREMBER, MD (0033476766784, AGrember@chu-grenoble.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time between the antibiotic prescription and the pleuropulmonary ultrasonography used to detect pneumonia (time frame: 1 hour). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026.